- Home
- GIGM vs ZLAB Comparison
GIGM vs ZLAB Comparison
Compare GIGM & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- ZLAB
- Stock Information
- Founded
- GIGM 1998
- ZLAB 2013
- Country
- GIGM Taiwan
- ZLAB China
- Employees
- GIGM N/A
- ZLAB N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- ZLAB Health Care
- Exchange
- GIGM Nasdaq
- ZLAB Nasdaq
- Market Cap
- GIGM 20.2M
- ZLAB 3.6B
- IPO Year
- GIGM 2000
- ZLAB 2017
- Fundamental
- Price
- GIGM $1.59
- ZLAB $28.46
- Analyst Decision
- GIGM
- ZLAB Buy
- Analyst Count
- GIGM 0
- ZLAB 6
- Target Price
- GIGM N/A
- ZLAB $57.22
- AVG Volume (30 Days)
- GIGM 12.1K
- ZLAB 554.8K
- Earning Date
- GIGM 10-28-2025
- ZLAB 11-06-2025
- Dividend Yield
- GIGM N/A
- ZLAB N/A
- EPS Growth
- GIGM N/A
- ZLAB N/A
- EPS
- GIGM N/A
- ZLAB N/A
- Revenue
- GIGM $3,250,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- GIGM N/A
- ZLAB $41.80
- Revenue Next Year
- GIGM N/A
- ZLAB $49.93
- P/E Ratio
- GIGM N/A
- ZLAB N/A
- Revenue Growth
- GIGM N/A
- ZLAB 32.56
- 52 Week Low
- GIGM $1.35
- ZLAB $23.82
- 52 Week High
- GIGM $1.89
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- GIGM 41.38
- ZLAB 34.57
- Support Level
- GIGM $1.62
- ZLAB $28.95
- Resistance Level
- GIGM $1.72
- ZLAB $30.18
- Average True Range (ATR)
- GIGM 0.06
- ZLAB 1.14
- MACD
- GIGM -0.01
- ZLAB -0.48
- Stochastic Oscillator
- GIGM 20.00
- ZLAB 7.82
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.